Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT)
Introduction Anthracyclines are included in chemotherapy regimens to treat several different types of cancer and are extremely effective. However, it is recognised that a significant side effect is cardiotoxicity; anthracyclines can cause irreversible damage to cardiac cells and ultimately impaired...
Saved in:
| Main Authors: | Richard Graham, Chris Plummer, Michael Stewart, David Austin, Adetayo S Kasim, Nasima Akhter, Helen C Hancock, Rebecca H Maier, Mark Verrill, Emmanuel Ogundimu, Jamie Maddox, Janine Graham, Andrew Wardley, Sophie Haney, Sharareh Vahabi, Helen Oxenham, Alison Humphreys, Nicola Cresti, Lisa Chang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/12/12/e066252.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Trastuzumab and cardiotoxicity
by: Petra Sertić, et al.
Published: (2024-01-01) -
Imaging of Cardiotoxicity
by: Jerry D. Glickson, et al.
Published: (2008-05-01) -
Carbamazepine Cardiotoxicity
by: J Gordon Millichap
Published: (1993-10-01) -
Cardiotoxicity of Anticancer Drugs
by: I. Maiborodin, et al.
Published: (2025-02-01) -
Cardiotoxicity in chemotherapeutic agents
by: Vitorino Modesto dos Santos, et al.
Published: (2021-03-01)